The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
Open Access
- 1 February 2009
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (2), 538-544
- https://doi.org/10.1210/jc.2008-2241
Abstract
Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The optimal dosing interval of 5 mg zoledronate is not known. Objective: Our objective was to determine the duration of antiresorptive action of a single 5-mg dose of iv zoledronate. Design, Setting, and Participants: We conducted a double-blind, randomized, placebo-controlled trial over 2 yr at an academic research center, in a volunteer sample of 50 postmenopausal women with osteopenia. Intervention: Intervention included 5 mg zoledronate. Main Outcome Measures: Biochemical markers of bone turnover and bone mineral density of the lumbar spine, proximal femur, and total body. Results: Compared with placebo, zoledronate treatment decreased mean levels of each of four markers of bone turnover by at least 38% (range 38–45%) for the duration of the study (P < 0.0001 for each marker). After 2 yr, bone mineral density was higher in the zoledronate group than the placebo group by an average of 5.7% (95% confidence interval = 4.0–7.4) at the lumbar spine, 3.9% (2.2–5.7) at the proximal femur, and 1.7% (0.8–2.5) at the total body (P < 0.0001 for each skeletal site). Between-groups differences in markers of bone turnover and bone mineral density were similar at 12 and 24 months. Mild secondary hyperparathyroidism was present throughout the study in the zoledronate group. Conclusion: The antiresorptive effects of a single 5-mg dose of zoledronate are sustained for at least 2 yr. The magnitudes of the effects on markers of bone turnover and bone mineral density are comparable at 12 and 24 months. Administration of zoledronate at intervals of up to 2 yr may be associated with antifracture efficacy; clinical trials to investigate this possibility are justified.Keywords
This publication has 17 references indexed in Scilit:
- Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 MonthsJournal of Bone and Mineral Research, 2008
- Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone StructureJournal of Bone and Mineral Research, 2008
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureThe New England Journal of Medicine, 2007
- Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic AcidClinical Cancer Research, 2007
- Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosisOsteoporosis International, 2007
- Bone turnover 18 months after a single intravenous dose of zoledronic acidInternational Journal of Clinical Practice, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 2007
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityThe New England Journal of Medicine, 2002
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.JCI Insight, 1997